Clinical Trial Update: FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating FOLFOXIRI with or without Bevacizumab as first-line therapy for patients with unresectable liver-only metastatic colorectal cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFOXIRI (folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin, irinotecan)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN